KCA
TVTX icon

KVP Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

KVP Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Sell
39,000
-52,000
-57% -$2.31M 1.63% 26
2026
Q1 		$2.7M Hold
91,000
– – 2.02% 17
2025
Q4 		$3.48M Buy
+91,000
New +$2.96M 3.36% 12

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KVP Capital Advisors's TVTX Position: Q2 2026 in Review

KVP Capital Advisors reduced its Travere Therapeutics (TVTX) stake by 57% in Q2 2026, selling an estimated $2.31M and leaving 39,000 shares worth $2.22M. The position accounts for 1.63% of the portfolio, ranked #26.

KVP Capital Advisors first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.48M in Q4 2025. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • KVP Capital Advisors held 39,000 shares of Travere Therapeutics worth $2.22M as of Q2 2026.
  • KVP Capital Advisors sold 52,000 Travere Therapeutics shares in Q2 2026, an estimated $2.31M.
  • Travere Therapeutics made up 1.63% of KVP Capital Advisors's portfolio in Q2 2026, its #26 holding.
  • KVP Capital Advisors first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • KVP Capital Advisors's Travere Therapeutics position peaked at $3.48M in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.